Paradiem’s Emergent Biosolutions EBS Stock Holding History

Paradiem’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-38,649	Closed	-$2.28M	–	103
2021 Q1	$2.28M	Buy	38,649 +17,329	+81%	+$1.77M	0.75%	65
2020 Q4	$2.29M	Buy	+21,320	New	+$1.96M	0.97%	50

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paradiem's EBS Position: Q2 2021 in Review

Paradiem sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 38,649 shares — an estimated $2.28M sold.

Paradiem first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $2.29M in Q4 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

Paradiem reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
Paradiem sold 38,649 Emergent Biosolutions shares in Q2 2021, an estimated $2.28M.
Paradiem first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
Paradiem's Emergent Biosolutions position peaked at $2.29M in Q4 2020.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Paradiem's 13F filing for Q2 2021, filed 16 Aug 2021.